Navigation Links
J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers
Date:4/30/2008

>

Power Circle

Provider Index Ratings

Score For Consumers

Group Health Cooperative 778 5

Premera Blue Cross 765 4

Regence BlueShield of Washington 738 3

Northwest Region Average 735 3

Regence BlueCross BlueShield of Oregon 733 3

Providence Health Plan 733 3

Kaiser Health Plan 732 3

Blue Cross of Idaho 695 2

Regence Blue Shield of Idaho is included in the study, but not ranked due to small sample size.
Included in the Northwest Region are: Idaho, Oregon and Washington.

Ohio

(Based on a 1,000-point scale)

J.D. Power.com

Power Circle

Provider Index Ratings

Score For Consumers

Humana 748 5

Medical Mutual 737 4

United Healthcare 736 3

Aetna 735 3

Ohio Region Average 735 3

Anthem BlueCross BlueShield 733 3

AultCare is included in the study, but not ranked due to small sample size.

Pennsylvania-Delaware
'/>"/>

SOURCE J.D. Power and Associates
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Inaugural Stanford International Pro-Am Winner A Remarkable Story in Determination And the Powerful Impact of St. Jude Childrens Research Hospital
2. Universal Dental Plan Employs Collective Buying Power
3. The SCOOTER Store Donates Power Chairs to Two Army Veterans With Limited Mobility
4. Empowering consumers with their health records
5. Your Business Card is a Powerful Marketing Tool
6. Mental Health Prescription Program Named Winner in URACs Best Practices in Consumer Empowerment and Protection Awards
7. Dubai Cares Announces 12 Country Plan to Educate and Empower Children in Developing Nations
8. The SCOOTER Store Donates Power Chair to Teenager Struggling With Rare Dwarfism
9. Understand the Power of Competitive Intelligence
10. J.D. Power and Associates Reports: HealthFusion Recognized for Providing an Outstanding Customer Service Experience
11. Center for Connected Health Presents Growing Evidence of the Benefits of Technology to Improve Patient Satisfaction and Empowerment
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:DaVita.com Promotes Kidney-Friendly Foods for Super Bowl(R) XLIII 2Health News:DaVita.com Promotes Kidney-Friendly Foods for Super Bowl(R) XLIII 3Health News:NutriSystem Expands Voluntary United States Recall of Peanut Butter Granola Breakfast Bar to Include Canada Due to Possible Peanut Corporation of America (PCA) Contamination and Potential Health Risk 2Health News:NutriSystem Expands Voluntary United States Recall of Peanut Butter Granola Breakfast Bar to Include Canada Due to Possible Peanut Corporation of America (PCA) Contamination and Potential Health Risk 3Health News:AMDL, Inc. Announces Final Closing of Private Placement of Senior Notes 2Health News:AMDL, Inc. Announces Final Closing of Private Placement of Senior Notes 3Health News:Kids Who Spend More Time Outdoors Have Better Vision 2Health News:Grasso leads technical team's response to HHS HIV/AIDS Bureau announcement 2Health News:Grasso leads technical team's response to HHS HIV/AIDS Bureau announcement 3Health News:Women's Heart Health a Critical Focus at Northwestern Memorial's Bluhm Cardiovascular Institute 2Health News:Women's Heart Health a Critical Focus at Northwestern Memorial's Bluhm Cardiovascular Institute 3
Breaking Medicine Technology:Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Dynatronics Receives 180-Day NASDAQ Extension 2Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 1NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 2NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 3AGA Institute and Horizon Therapeutics Launch Connect to Protect Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 12385 1AGA Institute and Horizon Therapeutics Launch Connect to Protect Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 12385 2AGA Institute and Horizon Therapeutics Launch Connect to Protect Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 12385 3Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 1Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 2Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 3Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 4Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 5